• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.

作者信息

Matsumoto Akihiro

机构信息

Department of Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan.

出版信息

J Gastroenterol. 2017 Jan;52(1):127-128. doi: 10.1007/s00535-016-1259-0. Epub 2016 Sep 24.

DOI:10.1007/s00535-016-1259-0
PMID:27665100
Abstract
摘要

相似文献

1
Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.乙型肝炎核心相关抗原：慢性乙型肝炎患者停止核苷（酸）类似物治疗的有力指标。
J Gastroenterol. 2017 Jan;52(1):127-128. doi: 10.1007/s00535-016-1259-0. Epub 2016 Sep 24.
2
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.停止 HBeAg 阴性慢性乙型肝炎长期核苷（酸）类似物治疗后的病毒和宿主反应。
J Infect Dis. 2016 Nov 15;214(10):1492-1497. doi: 10.1093/infdis/jiw412. Epub 2016 Sep 7.
3
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.核苷（酸）类似物仅能使大多数慢性乙型肝炎患者的乙型肝炎 e 抗原血清学转换暂时发生。
Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059. Epub 2010 Apr 8.
4
Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.核苷（酸）类似物治疗后乙型肝炎病毒表面抗原和核心相关抗原缓慢下降的慢性乙型肝炎患者。
J Med Virol. 2018 May;90(5):989-993. doi: 10.1002/jmv.25028. Epub 2018 Jan 30.
5
Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".关于“乙肝核心相关抗原动态变化及核苷（酸）类似物停药后临床复发风险”的信函
Clin Mol Hepatol. 2024 Apr;30(2):269-271. doi: 10.3350/cmh.2024.0064. Epub 2024 Jan 31.
6
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.不同效力的核苷（酸）类似物对乙型肝炎表面抗原和共价闭合环状 DNA 的降低作用。
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1004-10.e1. doi: 10.1016/j.cgh.2013.01.026. Epub 2013 Feb 1.
7
[Research advances in withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients].[慢性乙型肝炎患者核苷（酸）类似物停药的研究进展]
Zhonghua Gan Zang Bing Za Zhi. 2016 Sep 20;24(9):704-707. doi: 10.3760/cma.j.issn.1007-3418.2016.09.015.
8
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.核苷（酸）类似物长期有效治疗后乙型肝炎病毒特异性 T 细胞功能的恢复。
Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14.
9
Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.慢性乙型肝炎病毒感染的 HIV 患者长期使用核苷（酸）类似物的临床和病毒学结局。
AIDS. 2011 Jan 2;25(1):73-9. doi: 10.1097/QAD.0b013e328340fde2.
10
Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.核苷（酸）类似物治疗期间的乙型肝炎病毒（HBV）核心相关抗原与肝内HBV复制及肝细胞癌的发生发展相关。
J Infect Dis. 2016 Apr 1;213(7):1096-106. doi: 10.1093/infdis/jiv572. Epub 2015 Nov 29.

引用本文的文献

1
Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia.在病毒载量得到抑制的患者中，人类免疫缺陷病毒合并感染根据乙型肝炎 e 抗原状态对乙型肝炎病毒病毒标志物产生不同影响。
J Viral Hepat. 2023 Aug;30(8):700-709. doi: 10.1111/jvh.13857. Epub 2023 Jun 6.

本文引用的文献

1
Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.慢性乙型肝炎患者口服抗病毒治疗停药后复发的临床结局及预测因素
J Gastroenterol. 2016 Aug;51(8):830-9. doi: 10.1007/s00535-015-1153-1. Epub 2015 Dec 19.
2
AASLD guidelines for treatment of chronic hepatitis B.美国肝病研究学会慢性乙型肝炎治疗指南。
Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13.
3
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
《亚太地区乙型肝炎管理临床实践指南：2015年更新版》
Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.
4
Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.慢性乙型肝炎患者核苷（酸）类似物停药导致风险的预防指南。
Hepatol Res. 2014 Jan;44(1):1-8. doi: 10.1111/hepr.12108. Epub 2013 May 7.
5
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.长期恩替卡韦治疗可降低乙型肝炎病毒感染患者肝细胞癌的发生率。
Hepatology. 2013 Jul;58(1):98-107. doi: 10.1002/hep.26180. Epub 2013 Mar 6.
6
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎病毒感染的管理
J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20.
7
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.乙肝病毒抗原和 DNA 联合用于预测慢性乙型肝炎核苷（酸）类似物停药后复发。
Hepatol Res. 2012 Feb;42(2):139-49. doi: 10.1111/j.1872-034X.2011.00910.x. Epub 2011 Nov 22.
8
Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients.尽管严格遵循停药标准，拉米夫定的疗效仍不佳：一项针对乙型肝炎 e 抗原阴性慢性乙型肝炎患者的前瞻性临床研究。
J Gastroenterol Hepatol. 2011 Mar;26(3):456-60. doi: 10.1111/j.1440-1746.2010.06492.x.
9
Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.慢性乙型肝炎患者血清乙肝病毒核心相关抗原与肝内共价闭合环状DNA的相关性
J Med Virol. 2009 Jan;81(1):27-33. doi: 10.1002/jmv.21339.
10
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.恩替卡韦与拉米夫定治疗HBeAg阴性慢性乙型肝炎患者的比较
N Engl J Med. 2006 Mar 9;354(10):1011-20. doi: 10.1056/NEJMoa051287.